Showing results (301-310 of 454) with videos related to

Sort By:
Pageof 46
Rheumatology (Oxford, England)|July 31, 2001
Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot studyD J Wallace, M Linker-Israeli, D Hallegua, et al.
Lupus|March 26, 2011
High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosusN Firooz, D A Albert, D J Wallace, et al.
Arthritis and Rheumatism|January 1, 1979
Coexistent gout and rheumatoid arthritis. Case report and literature reviewD J Wallace, J R Klinenberg, D Morham, et al.
Lupus|December 1, 2009
Review: Male systemic lupus erythematosus: a review of sex disparities in this diseaseL-J Lu, D J Wallace, M L Ishimori, et al.
The American Journal of Medicine|September 1, 1990
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipidsD J Wallace, A L Metzger, V J Stecher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptidesR Stein, S V Govindan, M J Mattes, et al.
International Journal of Cancer|December 18, 2001
Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxiaR D Blumenthal, A Taylor, L Osorio, et al.
Molecular Immunology|December 1, 1995
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2S O Leung, D M Goldenberg, A S Dion, et al.
International Journal of Cancer|May 2, 1997
The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibodyM J Mattes, L B Shih, S V Govindan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study GroupF L Moffat, C M Pinsky, L Hammershaimb, et al.
Pageof 46